Apatinib plus paclitaxel versus paclitaxel monotherapy for platinum-resistant recurrent ovarian cancer treatment: A retrospective cohort study.
apatinib
paclitaxel
platinum-resistant recurrent ovarian cancer
safety profile
treatment efficacy
Journal
Journal of clinical pharmacy and therapeutics
ISSN: 1365-2710
Titre abrégé: J Clin Pharm Ther
Pays: England
ID NLM: 8704308
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
revised:
23
10
2022
received:
22
09
2022
accepted:
02
11
2022
pubmed:
21
11
2022
medline:
24
12
2022
entrez:
20
11
2022
Statut:
ppublish
Résumé
Apatinib, an oral antiangiogenic drug, exerts potential anti-tumour effects on platinum-resistant recurrent ovarian cancer (PROC). This study intended to evaluate the efficacy and safety of apatinib plus paclitaxel compared to paclitaxel monotherapy in PROC patients. This retrospective cohort study reviewed 70 PROC patients who received apatinib plus paclitaxel (apatinib plus paclitaxel group) (N = 32) or paclitaxel monotherapy (paclitaxel monotherapy group) (N = 38). The recommended regimens were as follows: paclitaxel (60 mg/m Disease control rate was elevated (84.4% vs. 60.5%, P = 0.028), whereas objective response rate only disclosed an increasing trend (lacked statistical significance) (37.5% vs. 18.4%, P = 0.074) in apatinib plus paclitaxel group compared with paclitaxel monotherapy group. Progression-free survival (median [95% confidence interval (CI)]: 5.0 [2.5-7.5] months vs. 3.8 [2.4-5.2] months, P = 0.033) and overall survival (median [95% CI]: 21.1 [13.2-29.0] months vs. 14.8 [11.4-18.2] months, P = 0.032) were both prolonged in apatinib plus paclitaxel group compared to paclitaxel monotherapy group, which were further verified in the multivariate Cox's proportional hazard regression analyses (both P < 0.050). Additionally, the incidence of each adverse event was not different between the two groups (all P > 0.050). Apatinib plus paclitaxel exhibits better efficacy and acceptable toxicity compared with paclitaxel monotherapy in PROC patients.
Substances chimiques
Paclitaxel
P88XT4IS4D
apatinib
5S371K6132
Pyridines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2264-2273Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
Gaona-Luviano P, Medina-Gaona LA, Magana-Perez K. Epidemiology of ovarian cancer. Chin Clin Oncol. 2020;9(4):47.
Chandra A, Pius C, Nabeel M, et al. Ovarian cancer: current status and strategies for improving therapeutic outcomes. Cancer Med. 2019;8(16):7018-7031.
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.
Glajzer J, Grabowski JP, Sehouli J, Pfisterer J. Recurrent treatment in ovarian cancer patients: what are the best regimens and the order they should Be given? Curr Treat Options Oncol. 2020;21(6):49.
Arend R, Westin SN, Coleman RL. Decision analysis for secondline maintenance treatment of platinum sensitive recurrent ovarian cancer: a review. Int J Gynecol Cancer. 2020;30(5):684-694.
Leung SOA, Konstantinopoulos PA. Advances in the treatment of platinum resistant epithelial ovarian cancer: an update on standard and experimental therapies. Expert Opin Investig Drugs. 2021;30(7):695-707.
Pujade-Lauraine E, Banerjee S, Pignata S. Management of Platinum-Resistant, relapsed epithelial ovarian cancer and new drug perspectives. J Clin Oncol. 2019;37(27):2437-2448.
Armstrong DK, Alvarez RD, Bakkum-Gamez JN, et al. Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(2):191-226.
Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302-1308.
Lavacchi D, Fancelli S, Gatta Michelet MR, Catalano M, Roviello G. REBECA trial: a new piece of the evidence for bevacizumab in platinum-resistant recurrent ovarian cancer. Transl Cancer Res. 2020;9(2):402-404.
Sekine M, Enomoto T, Watanabe Y, Katabuchi H, Yaegashi N, Aoki D. The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer. Int J Clin Oncol. 2021;26(11):2123-2129.
Tian S, Quan H, Xie C, et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 2011;102(7):1374-1380.
Cheng Y, Zhang J, Geng H, Qin S, Hua H. Multiline treatment combining apatinib with toptecan for platinum-resistant recurrent ovarian cancer patients: a report of three cases. Onco Targets Ther. 2018;11:1989-1995.
Qi J, Liu E, Yue H, Chen G, Liu Y, Chen J. Evaluation of safety and efficacy of apatinib combination with chemotherapy for ovarian cancer treatment: a systematic review and meta-analysis. Ann Palliat Med. 2021;10(9):9902-9913.
Chen W, Li Z, Zheng Z, Wu X. Efficacy and safety of low-dose apatinib in ovarian cancer patients with platinum-resistance or platinum-refractoriness: a single-center retrospective study. Cancer Med. 2020;9(16):5899-5907.
Zhang J, Li A, Jiang Q, Zheng F, Zhu H. Efficacy and safety of Apatinib treatment In platinum-resistant recurrent epithelial ovarian cancer: a real world study. Drug des Devel Ther. 2019;13:3913-3918.
Wang T, Tang J, Yang H, et al. Effect of Apatinib plus Pegylated liposomal doxorubicin vs Pegylated liposomal doxorubicin alone on platinum-resistant recurrent ovarian cancer: the APPROVE randomized clinical trial. JAMA Oncol. 2022;8(8):1169-1176.
Huang Q, Chu C, Tang J, Dai Z. Efficacy and safety of Apatinib combined with etoposide in patients with recurrent platinum-resistant epithelial ovarian cancer: a retrospective study. J Cancer. 2020;11(18):5353-5358.
Xia L, Peng J, Lou G, et al. Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study. J Immunother Cancer. 2022;10(1):e003831.
Lortholary A, Largillier R, Weber B, et al. Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des cancers Ovariens (GINECO). Ann Oncol. 2012;23(2):346-352.
Le T, Hopkins L, Baines KA, et al. Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer. Gynecol Oncol. 2006;102(1):49-53.
Qiu H, Li J, Liu Q, Tang M, Wang Y. Apatinib, a novel tyrosine kinase inhibitor, suppresses tumor growth in cervical cancer and synergizes with paclitaxel. Cell Cycle. 2018;17(10):1235-1244.
Hou C, Jiang ZZ, Pan B, Zhang XC, Liu YQ. A comparison of chemotherapy used with and without Apatinib for patients with ovarian carcinoma who progressed after standard regimens: a systematic review and meta-analysis. Evid Based Complement Alternat Med. 2021;2021:2292907-2292914.
Yang Y, Xia L, Wu Y, et al. Programmed death ligand-1 regulates angiogenesis and metastasis by participating in the c-JUN/VEGFR2 signaling axis in ovarian cancer. Cancer Commun. 2021;41(6):511-527.
Fathi Maroufi N, Rashidi MR, Vahedian V, Akbarzadeh M, Fattahi A, Nouri M. Therapeutic potentials of Apatinib in cancer treatment: possible mechanisms and clinical relevance. Life Sci. 2020;241:117106.
Komiyama S, Kugimiya T, Takeya C, Takahashi R, Kubushiro K. Platinum-resistant recurrent ovarian cancer with long survival on bevacizumab and gemcitabine. J Obstet Gynaecol Res. 2018;44(7):1330-1334.
Sait Bakir M, Birge O, Karadag C, et al. Bevacizumab in recurrent ovarian cancer. J BUON. 2021;26(4):1271-1278.
Castro IJ, Pons Busom M, Ballesteros Cabanas GI, et al. Study on the adverse reactions related to paclitaxel and docetaxel infusion. Farm Hosp. 2013;37(2):88-94.
Shao F, Zhang H, Yang X, Luo X, Liu J. Adverse events and management of apatinib in patients with advanced or metastatic cancers: a review. Neoplasma. 2020;67(4):715-723.